Junshi Biotech announced that the company received a notice from the FDA, and the application for clinical trials of the EGFR/HER3 bispecific antibody conjugate drug JS212 for the treatment of advanced solid tumors was approved by the FDA. JS212 is mainly used to treat advanced malignant solid tumors. Compared with single-target ADC drugs, it is expected to be effective for a wider range of tumors and can also be expected to overcome drug resistance problems.

Junshi Biotech announced that the company received a notice from the FDA, and the application for clinical trials of the EGFR/HER3 bispecific antibody conjugate drug JS212 for the treatment of advanced solid tumors was approved by the FDA. JS212 is mainly used to treat advanced malignant solid tumors. Compared with single-target ADC drugs, it is expected to be effective for a wider range of tumors and can also be expected to overcome drug resistance problems.